Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.

Shannon Stockton,Paul Catalano,Steven J Cohen,Barbara A Burtness,Edith P Mitchell,Efrat Dotan,Sam J Lubner,Pankaj Kumar,Mary F Mulcahy,George A Fisher, Theodore L Crandall,Al Benson

The oncologist（2023）

引用 0|浏览12

暂无评分

摘要

The addition of cixutumumab to paclitaxel in second-line therapy of metastatic esophageal/GEJ cancer was well tolerated but did not improve clinical outcomes relative to standard of care (ClinicalTrials.gov Identifier: NCT01142388).

查看译文

关键词

esophageal,gastroesophageal junction,insulin-like growth factor-1 receptor,xixutumumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要